Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Darolutamide/ADT Combo Delays Pain Progression and Enhances QOL in mHSPC

June 11th 2025

Alicia Morgans, MD, MPH, discusses findings from a QOL analysis of the ARANOTE trial, which evaluated darolutamide plus ADT in patients with mHSPC.

Mayo Clinic Takes the Next Step in Making Heavy Particle Therapy Available in the Western Hemisphere for Patients with Aggressive Cancers

June 11th 2025

The Mayo Clinic's new facility will house the first carbon ion therapy program in the Western Hemisphere.

Olaparib Plus Radium-223 Doubles rPFS vs Radium-223 Alone in mCRPC

June 10th 2025

Rana R. McKay, MD, discusses data from the COMRADE trial, which showed that olaparib plus radium-223 improved rPFS in men with mCRPC with bone metastases.

The OncFive: Top Oncology Updates for the Week of 6/1

June 7th 2025

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

Dr Saad on the FDA Approval of Darolutamide in mCSPC

June 4th 2025

Fred Saad, MD, discusses the FDA’s approval of darolutamide without chemotherapy for metastatic castration-sensitive prostate cancer

Olaparib Plus Radium-223 Generates Superior rPFS in CRPC

June 3rd 2025

Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.

CAN-2409 Plus EBRT Bests EBRT Alone in High-Risk Localized Prostate Cancer

June 3rd 2025

CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025

The FDA has approved darolutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer

June 3rd 2025

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

CHMP Shares Positive Opinion for Denosumab Biosimilars for Osteoporosis and Skeletal-Related Cancer Complications

June 3rd 2025

The European Medicines Agency's CHMP has recommended the use of denosumab biosimilars referencing Prolia and Xgeva in all reference product indications.

Niraparib/Abiraterone Is Effective for HRR+ Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025

Niraparib plus abiraterone acetate and prednisone improved rPFS vs abiraterone acetate and prednisone and placebo in patients with mCSPC with alterations in HRR genes.

Lutetium Lu 177 Vipivotide Tetraxetan Generates rPFS Improvement in PSMA+ mHSPC

June 2nd 2025

Lutetium Lu 177 vipivotide tetraxetan plus hormone therapy yielded rPFS and OS benefits vs hormone therapy alone in patients with PSMA-positive mHSPC.

ORIC-944 Plus AR Inhibition Yields PSA Responses in mCRPC

May 29th 2025

The addition of ORIC-944 to an AR pathway inhibitor generated PSA responses in metastatic castration-resistant prostate cancer.

Five Under 5: Top Oncology Videos for the Week of 5/18

May 25th 2025

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

The OncFive: Top Oncology Articles for the Week of 5/18

May 24th 2025

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications

May 22nd 2025

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

FDA Votes Against Risk/Benefit Profile of Talazoparib Plus Enzalutamide for Non-HRR–Mutant mCRPC

May 21st 2025

The FDA’s ODAC voted 8 to 0 against the risk/benefit profile of talazoparib in combination with enzalutamide for patients with non-HRR–mutant mCRPC.

Five Under 5: Top Oncology Videos for the Week of 5/11

May 18th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Dr Garcia on the Safety of Earlier Use of Lu 177 Vipivotide Tetraxetan PSMA+ mCRPC

May 16th 2025

Jorge A. Garcia, MD, discusses the safety of Lu 177 vipivotide tetraxetan earlier in the treatment course for PSMA–positive mCRPC.

Dr Yu on Factors Influencing PARP Inhibitor Selection in mCRPC

May 16th 2025

Evan Ya-Wen Yu, MD, discusses the PARP inhibitors that are available for the treatment of patients with mCRPC.